{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T05:12:04Z","timestamp":1781413924676,"version":"3.54.1"},"reference-count":128,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T00:00:00Z","timestamp":1736812800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000005","name":"US Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Steroid Biochemistry and Molecular Biology"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.jsbmb.2025.106675","type":"journal-article","created":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T19:44:28Z","timestamp":1737143068000},"page":"106675","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["The double disparity: Vitamin D deficiency and lethal prostate cancer in black men"],"prefix":"10.1016","volume":"247","author":[{"given":"Adriana","family":"Duraki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten D.","family":"Krieger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0852-7726","authenticated-orcid":false,"given":"Larisa","family":"Nonn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.jsbmb.2025.106675_bib1","first-page":"794","article-title":"Effect of serum 25-hydroxyvitamin D level on lung, breast, colorectal and prostate cancers: a nested case-control study","volume":"26","author":"Acikgoz","year":"2020","journal-title":"East. Mediterr. Health J. = La Rev. De. Sante De. La Mediterr. Orient. = Al-Majallah Al-Sihhiyah Li-Sharq Al-Mutawassit"},{"issue":"11","key":"10.1016\/j.jsbmb.2025.106675_bib2","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1093\/jnci\/djn152","article-title":"Serum vitamin D concentration and prostate cancer risk: a nested case-control study","volume":"100","author":"Ahn","year":"2008","journal-title":"J. Natl. Cancer Inst."},{"issue":"9","key":"10.1016\/j.jsbmb.2025.106675_bib3","first-page":"847","article-title":"Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland)","volume":"11","author":"Ahonen","year":"2000","journal-title":"Cancer Causes Control.: CCC"},{"issue":"9","key":"10.1016\/j.jsbmb.2025.106675_bib4","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1158\/1055-9965.EPI-11-0403","article-title":"Serum 25-hydroxy vitamin D and prostate cancer risk in a large nested case-control study","volume":"20","author":"Albanes","year":"2011","journal-title":"Cancer Epidemiol. Biomark. Prev.: A Publ. Am. Assoc. Cancer Res. Cosponsored Am. Soc. Prev. Oncol."},{"key":"10.1016\/j.jsbmb.2025.106675_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/pore.2022.1610246","article-title":"Association between vitamin D binding protein gene polymorphism (Rs7041), vitamin D receptor, and 25-hydroxyvitamin D serum levels with prostate cancer in Kurdish population in west of Iran","volume":"28","author":"Amiri","year":"2022","journal-title":"Pathol. Oncol. Res.: POR"},{"issue":"6","key":"10.1016\/j.jsbmb.2025.106675_bib6","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.7314\/APJCP.2015.16.6.2227","article-title":"The Fok1 vitamin D receptor gene polymorphism and 25(OH) D serum levels and prostate cancer among Jordanian men","volume":"16","author":"Atoum","year":"2015","journal-title":"Asian Pac. J. Cancer Prev.: APJCP"},{"issue":"8","key":"10.1016\/j.jsbmb.2025.106675_bib7","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1158\/1078-0432.CCR-07-4274","article-title":"Randomized, double-blinded phase II evaluation of docetaxel with or without doxercalciferol in patients with metastatic, androgen-independent prostate cancer","volume":"14","author":"Attia","year":"2008","journal-title":"Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res."},{"issue":"8","key":"10.1016\/j.jsbmb.2025.106675_bib8","first-page":"1297","article-title":"Serum 25-OH vitamin D levels and risk of developing prostate cancer in older men","volume":"21","author":"Barnett","year":"2010","journal-title":"Cancer Causes Control.: CCC"},{"issue":"3","key":"10.1016\/j.jsbmb.2025.106675_bib9","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1158\/1055-9965.EPI-04-0319","article-title":"Risk of prostate cancer in a randomized clinical trial of calcium supplementation","volume":"14","author":"Baron","year":"2005","journal-title":"Cancer Epidemiol. Biomark. Prev.: A Publ. Am. Assoc. Cancer Res. Cosponsored Am. Soc. Prev. Oncol."},{"issue":"1","key":"10.1016\/j.jsbmb.2025.106675_bib10","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12885-017-3060-8","article-title":"Race and BMI modify associations of calcium and vitamin D intake with prostate cancer","volume":"17","author":"Batai","year":"2017","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.jsbmb.2025.106675_bib11","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1200\/jco.2003.05.117","article-title":"Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer","volume":"21","author":"Beer","year":"2003","journal-title":"J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.jsbmb.2025.106675_bib12","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/01.coc.0000136020.27904.9c","article-title":"High-dose calcitriol and carboplatin in metastatic androgen-independent prostate cancer","volume":"27","author":"Beer","year":"2004","journal-title":"Am. J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.jsbmb.2025.106675_bib13","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1002\/cncr.11179","article-title":"High-dose weekly oral calcitriol in patients with a rising PSA after prostatectomy or radiation for prostate carcinoma","volume":"97","author":"Beer","year":"2003","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.jsbmb.2025.106675_bib14","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1200\/JCO.2006.06.8197","article-title":"Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT investigators","volume":"25","author":"Beer","year":"2007","journal-title":"J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.jsbmb.2025.106675_bib15","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/S0090-4295(02)01991-X","article-title":"Calcium intake and prostate cancer risk in a long-term aging study: the Baltimore longitudinal study of aging","volume":"60","author":"Berndt","year":"2002","journal-title":"Urology"},{"issue":"8","key":"10.1016\/j.jsbmb.2025.106675_bib16","first-page":"1377","article-title":"Vitamin D, PTH, and calcium and the risk of prostate cancer: a prospective nested case-control study","volume":"23","author":"Br\u00e4ndstedt","year":"2012","journal-title":"Cancer Causes Control.: CCC"},{"issue":"5","key":"10.1016\/j.jsbmb.2025.106675_bib17","first-page":"669","article-title":"Vitamin D, PTH, and calcium in relation to survival following prostate cancer","volume":"27","author":"Br\u00e4ndstedt","year":"2016","journal-title":"Cancer Causes Control.: CCC"},{"issue":"3","key":"10.1016\/j.jsbmb.2025.106675_bib18","first-page":"235","article-title":"Prostate cancer and prediagnostic levels of serum vitamin D metabolites (Maryland, United States)","volume":"6","author":"Braun","year":"1995","journal-title":"Cancer Causes Control.: CCC"},{"issue":"9","key":"10.1016\/j.jsbmb.2025.106675_bib19","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1002\/cncr.24973","article-title":"Phase 2 trial of weekly intravenous 1,25 dihydroxy cholecalciferol (Calcitriol) in combination with dexamethasone for castration-resistant prostate cancer","volume":"116","author":"Chadha","year":"2010","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.jsbmb.2025.106675_bib20","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1111\/j.1464-410X.2008.08017.x","article-title":"A phase II study of high-dose calcitriol combined with mitoxantrone and prednisone for androgen-independent prostate cancer","volume":"102","author":"Chan","year":"2008","journal-title":"BJU Int."},{"issue":"6","key":"10.1016\/j.jsbmb.2025.106675_bib21","first-page":"559","article-title":"Dairy products, calcium, phosphorous, vitamin D, and risk of prostate cancer (Sweden)","volume":"9","author":"Chan","year":"1998","journal-title":"Cancer Causes Control.: CCC"},{"issue":"9","key":"10.1016\/j.jsbmb.2025.106675_bib22","first-page":"859","article-title":"Diet and prostate cancer risk in a cohort of smokers, with a specific focus on calcium and phosphorus (Finland)","volume":"11","author":"Chan","year":"2000","journal-title":"Cancer Causes Control.: CCC"},{"issue":"9","key":"10.1016\/j.jsbmb.2025.106675_bib23","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1158\/1055-9965.EPI-14-0522","article-title":"Null association between vitamin D and PSA levels among black men in a vitamin D supplementation trial","volume":"23","author":"Chandler","year":"2014","journal-title":"Cancer Epidemiol. Biomark. Prev.: A Publ. Am. Assoc. Cancer Res. Cosponsored Am. Soc. Prev. Oncol."},{"issue":"3","key":"10.1016\/j.jsbmb.2025.106675_bib24","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1159\/000485512","article-title":"The association between serum 25-hydroxyvitamin D and cancer risk: results from the prospective KORA F4 study","volume":"41","author":"Cheney","year":"2018","journal-title":"Oncol. Res. Treat."},{"issue":"October","key":"10.1016\/j.jsbmb.2025.106675_bib25","article-title":"Are vitamins relevant to cancer risks? A mendelian randomization investigation","volume":"78","author":"Cheng","year":"2020","journal-title":"Nutrition (Burbank, Los Angeles County, Calif.)"},{"issue":"5","key":"10.1016\/j.jsbmb.2025.106675_bib26","first-page":"467","article-title":"Vitamin D and Prostate cancer: a prediagnostic study with stored sera","volume":"2","author":"Corder","year":"1993","journal-title":"Cancer Epidemiol. Biomark. Prevent.: A Publ. Am. Assoc. Cancer Res. Cosponsored Am. Soc. Prev. Oncol."},{"issue":"5","key":"10.1016\/j.jsbmb.2025.106675_bib27","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1080\/01635581.2024.2328378","article-title":"Association between pretreatment blood 25-hydroxyvitamin D level and survival outcomes in patients with clinically localized prostate cancer: an updated meta-analysis","volume":"76","author":"Cui","year":"2024","journal-title":"Nutr. Cancer"},{"issue":"3\u20134","key":"10.1016\/j.jsbmb.2025.106675_bib28","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/sj.bjc.6690396","article-title":"Foods, nutrients and prostate cancer: a case-control study in Uruguay","volume":"80","author":"Deneo-Pellegrini","year":"1999","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.jsbmb.2025.106675_bib29","doi-asserted-by":"crossref","first-page":"81","DOI":"10.7205\/MILMED-D-12-00540","article-title":"Vitamin D and prostate cancer survival in veterans","volume":"179","author":"Der","year":"2014","journal-title":"Mil. Med."},{"issue":"2","key":"10.1016\/j.jsbmb.2025.106675_bib30","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1017\/S0007114515004353","article-title":"A prospective study of plasma 25-hydroxyvitamin D concentration and prostate cancer risk","volume":"115","author":"Deschasaux","year":"2016","journal-title":"Br. J. Nutr."},{"key":"10.1016\/j.jsbmb.2025.106675_bib31","article-title":"Circulating vitamin D concentration and risk of seven cancers: mendelian randomisation study","volume":"359","author":"Dimitrakopoulou","year":"2017","journal-title":"BMJ (Clin. Res. Ed.)"},{"issue":"4","key":"10.1016\/j.jsbmb.2025.106675_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0018625","article-title":"Prediagnostic plasma vitamin D metabolites and mortality among patients with prostate cancer","volume":"6","author":"Fang","year":"2011","journal-title":"PloS One"},{"issue":"12","key":"10.1016\/j.jsbmb.2025.106675_bib33","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1158\/1055-9965.EPI-07-0672","article-title":"Lack of association between serum levels of 25-hydroxyvitamin D and the subsequent risk of prostate cancer in Finnish men","volume":"16","author":"Faupel-Badger","year":"2007","journal-title":"Cancer Epidemiol. Biomark. Prev.: A Publ. Am. Assoc. Cancer Res. Cosponsored Am. Soc. Prev. Oncol."},{"issue":"5","key":"10.1016\/j.jsbmb.2025.106675_bib34","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nrc3691","article-title":"The role of vitamin D in reducing cancer risk and progression","volume":"14","author":"Feldman","year":"2014","journal-title":"Nat. Rev. Cancer"},{"issue":"2","key":"10.1016\/j.jsbmb.2025.106675_bib35","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/cncr.21982","article-title":"A Phase II trial of dexamethasone, vitamin D, and carboplatin in patients with hormone-refractory prostate cancer","volume":"107","author":"Flaig","year":"2006","journal-title":"Cancer"},{"issue":"21","key":"10.1016\/j.jsbmb.2025.106675_bib36","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1093\/jnci\/djm204","article-title":"Prospective study of serum vitamin D and cancer mortality in the United States","volume":"99","author":"Freedman","year":"2007","journal-title":"J. Natl. Cancer Inst."},{"issue":"3\u20134","key":"10.1016\/j.jsbmb.2025.106675_bib37","first-page":"329","article-title":"Serum 25-hydroxy vitamin D levels in bulgarian patients with prostate cancer: a pilot study","volume":"61","author":"Galunska","year":"2015","journal-title":"Clin. Lab."},{"issue":"6","key":"10.1016\/j.jsbmb.2025.106675_bib38","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1002\/ijc.25439","article-title":"Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma","volume":"128","author":"Gandini","year":"2011","journal-title":"Int. J. Cancer"},{"issue":"2","key":"10.1016\/j.jsbmb.2025.106675_bib39","first-page":"121","article-title":"Circulating vitamin D metabolites in relation to subsequent development of prostate cancer","volume":"5","author":"Gann","year":"1996","journal-title":"Cancer Epidemiol. Biomark. Prevent.: A Publ. Am. Assoc. Cancer Res. Cosponsored Am. Soc. Prev. Oncol."},{"issue":"January","key":"10.1016\/j.jsbmb.2025.106675_bib40","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2147\/TCRM.S149325","article-title":"Circulating vitamin D concentration and risk of prostate cancer: a dose\u2013response meta-analysis of prospective studies","volume":"14","author":"Gao","year":"2018","journal-title":"Ther. Clin. Risk Manag."},{"issue":"9","key":"10.1016\/j.jsbmb.2025.106675_bib41","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/pros.22644","article-title":"Phase II open label, multi-center clinical trial of modulation of intermediate endpoint biomarkers by 1\u03b1-hydroxyvitamin D2 in patients with clinically localized prostate cancer and high grade pin","volume":"73","author":"Gee","year":"2013","journal-title":"Prostate"},{"issue":"3","key":"10.1016\/j.jsbmb.2025.106675_bib42","first-page":"319","article-title":"Associations of circulating and dietary vitamin D with prostate cancer risk: a systematic review and dose-response meta-analysis","volume":"22","author":"Gilbert","year":"2011","journal-title":"Cancer Causes Control.: CCC"},{"issue":"5","key":"10.1016\/j.jsbmb.2025.106675_bib43","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1002\/ijc.27327","article-title":"Associations of circulating 25-hydroxyvitamin D with prostate cancer diagnosis, stage and grade","volume":"131","author":"Gilbert","year":"2012","journal-title":"Int. J. Cancer J. Int. Du Cancer"},{"issue":"7","key":"10.1016\/j.jsbmb.2025.106675_bib44","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1093\/jnci\/djj101","article-title":"Prospective study of predictors of vitamin D status and cancer incidence and mortality in men","volume":"98","author":"Giovannucci","year":"2006","journal-title":"J. Natl. Cancer Inst."},{"issue":"3","key":"10.1016\/j.jsbmb.2025.106675_bib45","first-page":"442","article-title":"Calcium and fructose intake in relation to risk of prostate cancer","volume":"58","author":"Giovannucci","year":"1998","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.jsbmb.2025.106675_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/S0022-5347(01)63236-1","article-title":"Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (Calcitriol)","volume":"159","author":"Gross","year":"1998","journal-title":"J. Urol."},{"issue":"3","key":"10.1016\/j.jsbmb.2025.106675_bib47","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0119690","article-title":"The association between pre-treatment serum 25-hydroxyvitamin D and survival in newly diagnosed stage IV prostate cancer","volume":"10","author":"Gupta","year":"2015","journal-title":"PloS One"},{"issue":"5","key":"10.1016\/j.jsbmb.2025.106675_bib48","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1158\/1055-9965.EPI-18-1155","article-title":"Circulating 25-hydroxyvitamin D concentration and risk of breast, prostate, and colorectal cancers: the melbourne collaborative cohort study","volume":"28","author":"Heath","year":"2019","journal-title":"Cancer Epidemiol. Biomark. Prev.: A Publ. Am. Assoc. Cancer Res. Cosponsored Am. Soc. Prev. Oncol."},{"issue":"5","key":"10.1016\/j.jsbmb.2025.106675_bib49","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.canep.2013.07.005","article-title":"Circulating levels of 25-hydroxyvitamin D and prostate cancer prognosis","volume":"37","author":"Holt","year":"2013","journal-title":"Cancer Epidemiol."},{"issue":"13","key":"10.1016\/j.jsbmb.2025.106675_bib50","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1002\/pros.21180","article-title":"Vitamin D pathway gene variants and prostate cancer prognosis","volume":"70","author":"Holt","year":"2010","journal-title":"Prostate"},{"issue":"6","key":"10.1016\/j.jsbmb.2025.106675_bib51","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1158\/1055-9965.EPI-09-0113","article-title":"Vitamin D pathway gene variants and prostate cancer risk","volume":"18","author":"Holt","year":"2009","journal-title":"Cancer Epidemiol. Biomark. Prev.: A Publ. Am. Assoc. Cancer Res. Cosponsored Am. Soc. Prev. Oncol."},{"issue":"4","key":"10.1016\/j.jsbmb.2025.106675_bib52","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1080\/01635580801911779","article-title":"Dairy products, dietary calcium and vitamin D intake as risk factors for prostate cancer: a meta-analysis of 26,769 cases from 45 observational studies","volume":"60","author":"Huncharek","year":"2008","journal-title":"Nutr. Cancer"},{"issue":"6","key":"10.1016\/j.jsbmb.2025.106675_bib53","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1002\/cam4.457","article-title":"Both serum 25-hydroxyvitamin D and calcium levels may increase the risk of incident prostate cancer in Caribbean men of African ancestry","volume":"4","author":"Jackson","year":"2015","journal-title":"Cancer Med."},{"issue":"1\u20135","key":"10.1016\/j.jsbmb.2025.106675_bib54","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jsbmb.2004.03.063","article-title":"Plasma levels of 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D and the risk of prostate cancer","volume":"89\u201390","author":"Jacobs","year":"2004","journal-title":"J. Steroid Biochem. Mol. Biol."},{"issue":"5","key":"10.1016\/j.jsbmb.2025.106675_bib55","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1093\/ije\/dyy284","article-title":"Circulating vitamin D concentrations and risk of breast and prostate cancer: a mendelian randomization study","volume":"48","author":"Jiang","year":"2019","journal-title":"Int. J. Epidemiol."},{"issue":"5","key":"10.1016\/j.jsbmb.2025.106675_bib56","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/bjc.1997.445","article-title":"A case-control study of diet and prostate cancer","volume":"76","author":"Key","year":"1997","journal-title":"Br. J. Cancer"},{"issue":"3","key":"10.1016\/j.jsbmb.2025.106675_bib57","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0960-0760(98)00054-5","article-title":"Localization of 1,25-dihydroxyvitamin D3 receptor (VDR) expression in human prostate","volume":"66","author":"Kivineva","year":"1998","journal-title":"J. Steroid Biochem. Mol. Biol."},{"issue":"4","key":"10.1016\/j.jsbmb.2025.106675_bib58","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/jcb.1185","article-title":"Expression patterns of vitamin D receptor in human prostate","volume":"82","author":"Krill","year":"2001","journal-title":"J. Cell. Biochem."},{"issue":"5","key":"10.1016\/j.jsbmb.2025.106675_bib59","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1093\/aje\/kwq148","article-title":"Diet, supplement use, and prostate cancer risk: results from the prostate cancer prevention trial","volume":"172","author":"Kristal","year":"2010","journal-title":"Am. J. Epidemiol."},{"issue":"8","key":"10.1016\/j.jsbmb.2025.106675_bib60","first-page":"719","article-title":"Associations of energy, fat, calcium, and vitamin D with prostate cancer risk","volume":"11","author":"Kristal","year":"2002","journal-title":"Cancer Epidemiol. Biomark. Prev.: A Publ. Am. Assoc. Cancer Res. Cosponsored Am. Soc. Prev. Oncol."},{"issue":"8","key":"10.1016\/j.jsbmb.2025.106675_bib61","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1158\/1055-9965.EPI-14-0115","article-title":"Plasma Vitamin D and prostate cancer risk: results from the selenium and vitamin E cancer prevention trial","volume":"23","author":"Kristal","year":"2014","journal-title":"Cancer Epidemiol. Biomark. Prev.: A Publ. Am. Assoc. Cancer Res. Cosponsored Am. Soc. Prev. Oncol."},{"issue":"14","key":"10.1016\/j.jsbmb.2025.106675_bib62","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1002\/cncr.30634","article-title":"Serum 25-hydroxyvitamin D, vitamin D binding protein, and prostate cancer risk in black men","volume":"123","author":"Layne","year":"2017","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.jsbmb.2025.106675_bib63","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0040103","article-title":"A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer","volume":"4","author":"Li","year":"2007","journal-title":"PLoS Med."},{"issue":"11","key":"10.1016\/j.jsbmb.2025.106675_bib64","first-page":"4077","article-title":"Phase II study of 1alpha-hydroxyvitamin D(2) in the treatment of advanced androgen-independent prostate cancer","volume":"9","author":"Liu","year":"2003","journal-title":"Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res."},{"issue":"April","key":"10.1016\/j.jsbmb.2025.106675_bib65","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.canlet.2022.01.028","article-title":"Racial disparities in prostate cancer: a complex interplay between socioeconomic inequities and genomics","volume":"531","author":"Lowder","year":"2022","journal-title":"Cancer Lett."},{"issue":"5","key":"10.1016\/j.jsbmb.2025.106675_bib66","first-page":"385","article-title":"Vitamin D receptor polymorphisms, circulating vitamin D metabolites, and risk of prostate cancer in United States physicians","volume":"7","author":"Ma","year":"1998","journal-title":"Cancer Epidemiol. Biomark. Prevent.: Publ. Am. Assoc. Cancer Res. Cosponsored Am. Soc. Prev. Oncol."},{"issue":"1","key":"10.1016\/j.jsbmb.2025.106675_bib67","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa1809944","article-title":"Vitamin D supplements and prevention of cancer and cardiovascular disease","volume":"380","author":"Manson","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.jsbmb.2025.106675_bib68","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1210\/jc.2012-1451","article-title":"Vitamin D3 supplementation at 4000 international units per day for one year results in a decrease of positive cores at repeat biopsy in subjects with low-risk prostate cancer under active surveillance","volume":"97","author":"Marshall","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"7853","key":"10.1016\/j.jsbmb.2025.106675_bib69","first-page":"325","article-title":"The story of vitamin D: from vitamin to hormone","volume":"1","author":"Mason","year":"1974","journal-title":"Lancet."},{"issue":"4","key":"10.1016\/j.jsbmb.2025.106675_bib70","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2991\/jegh.k.191008.001","article-title":"Current cancer epidemiology","volume":"9","author":"Mattiuzzi","year":"2019","journal-title":"J. Epidemiol. Glob. Health"},{"key":"10.1016\/j.jsbmb.2025.106675_bib71","series-title":"The Differentiation of Patient-Derived Prostate Organoids and the Influence of Vitamin D","author":"McCray","year":"2020"},{"issue":"1","key":"10.1016\/j.jsbmb.2025.106675_bib72","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3945\/ajcn.112.039222","article-title":"Vitamin D, season, and risk of prostate cancer: a nested case-control study within Norwegian health studies","volume":"97","author":"Meyer","year":"2013","journal-title":"Am. J. Clin. Nutr."},{"issue":"3","key":"10.1016\/j.jsbmb.2025.106675_bib73","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0151441","article-title":"Long term association between serum 25-hydroxyvitamin D and mortality in a cohort of 4379 men","volume":"11","author":"Meyer","year":"2016","journal-title":"PloS One"},{"issue":"4","key":"10.1016\/j.jsbmb.2025.106675_bib74","doi-asserted-by":"crossref","first-page":"841","DOI":"10.3945\/ajcn.2010.29749","article-title":"Plasma vitamin D and mortality in older men: a community-based prospective cohort study","volume":"92","author":"Micha\u00eblsson","year":"2010","journal-title":"Am. J. Clin. Nutr."},{"issue":"9","key":"10.1016\/j.jsbmb.2025.106675_bib75","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1002\/pros.20570","article-title":"Vitamin D receptor (VDR) gene polymorphisms and haplotypes, interactions with plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D, and prostate cancer risk","volume":"67","author":"Mikhak","year":"2007","journal-title":"Prostate"},{"issue":"4","key":"10.1016\/j.jsbmb.2025.106675_bib76","doi-asserted-by":"crossref","first-page":"378","DOI":"10.3390\/nu9040378","article-title":"Interactions of the insulin-like growth factor axis and vitamin D in prostate cancer risk in the prostate cancer prevention trial","volume":"9","author":"Miles","year":"2017","journal-title":"Nutrients"},{"issue":"4","key":"10.1016\/j.jsbmb.2025.106675_bib77","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1158\/1055-9965.EPI-15-0991","article-title":"Circulating 25-hydroxyvitamin D and prostate cancer survival","volume":"25","author":"Mondul","year":"2016","journal-title":"Cancer Epidemiol. Biomark. Prev.: A Publ. Am. Assoc. Cancer Res. Cosponsored Am. Soc. Prev. Oncol."},{"issue":"9","key":"10.1016\/j.jsbmb.2025.106675_bib78","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1002\/cncr.20185","article-title":"High-dose calcitriol, zoledronate, and dexamethasone for the treatment of progressive prostate carcinoma","volume":"100","author":"Morris","year":"2004","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.jsbmb.2025.106675_bib79","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1158\/1078-0432.CCR-13-3085","article-title":"Vitamin D deficiency predicts prostate biopsy outcomes","volume":"20","author":"Murphy","year":"2014","journal-title":"Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res."},{"issue":"1","key":"10.1016\/j.jsbmb.2025.106675_bib80","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3390\/nu9010012","article-title":"Association between serum 25-hydroxy-vitamin D and aggressive prostate cancer in African American men","volume":"9","author":"Nelson","year":"2016","journal-title":"Nutrients"},{"issue":"9","key":"10.1016\/j.jsbmb.2025.106675_bib81","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1111\/j.1464-410X.2009.08599.x","article-title":"The promiscuous receptor","volume":"104","author":"Newsom-Davis","year":"2009","journal-title":"BJU Int."},{"issue":"4","key":"10.1016\/j.jsbmb.2025.106675_bib82","first-page":"425","article-title":"Serum vitamin D metabolite levels and the subsequent development of prostate cancer (Hawaii, United States)","volume":"9","author":"Nomura","year":"1998","journal-title":"Cancer Causes Control.: CCC"},{"issue":"12","key":"10.1016\/j.jsbmb.2025.106675_bib83","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1200\/JCO.2015.65.1463","article-title":"Associations between serum vitamin D and adverse pathology in men undergoing radical prostatectomy","volume":"34","author":"Nyame","year":"2016","journal-title":"J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.jsbmb.2025.106675_bib84","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/s41467-020-20368-w","article-title":"A comprehensive re-assessment of the association between vitamin D and cancer susceptibility using mendelian randomization","volume":"12","author":"Ong","year":"2021","journal-title":"Nat. Commun."},{"issue":"24","key":"10.1016\/j.jsbmb.2025.106675_bib85","first-page":"4315","article-title":"Vitamin D and overall cancer risk and cancer mortality: a mendelian randomization study","volume":"27","author":"Ong","year":"2018","journal-title":"Hum. Mol. Genet."},{"issue":"5","key":"10.1016\/j.jsbmb.2025.106675_bib86","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1158\/1055-9965.EPI-12-1332","article-title":"Serum 25-hydroxyvitamin d and cancer risk in older adults: results from a large German prospective cohort study","volume":"22","author":"Ord\u00f3\u00f1ez-Mena","year":"2013","journal-title":"Cancer Epidemiol. Biomark. Prev.: A Publ. Am. Assoc. Cancer Res. Cosponsored Am. Soc. Prev. Oncol."},{"issue":"5","key":"10.1016\/j.jsbmb.2025.106675_bib87","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/1078-1439(95)00061-5","article-title":"Phase II Trial of Oral 1,25-dihydroxyvitamin D (Calcitriol) in hormone refractory prostate cancer","volume":"1","author":"Osborn","year":"1995","journal-title":"Urol. Oncol."},{"issue":"13","key":"10.1016\/j.jsbmb.2025.106675_bib88","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1002\/pros.23018","article-title":"Risk of prostate cancer in African-American men: evidence of mixed effects of dietary quercetin by serum vitamin D status","volume":"75","author":"Paller","year":"2015","journal-title":"Prostate"},{"issue":"5","key":"10.1016\/j.jsbmb.2025.106675_bib89","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.ejca.2009.12.030","article-title":"Plasma 25-hydroxyvitamin D and prostate cancer risk: the multiethnic cohort","volume":"46","author":"Park","year":"2010","journal-title":"Eur. J. Cancer (Oxf. Engl.: 1990)"},{"issue":"11","key":"10.1016\/j.jsbmb.2025.106675_bib90","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1093\/aje\/kwm269","article-title":"Calcium, vitamin D, and dairy product intake and prostate cancer risk: the multiethnic cohort study","volume":"166","author":"Park","year":"2007","journal-title":"Am. J. Epidemiol."},{"issue":"10","key":"10.1016\/j.jsbmb.2025.106675_bib91","first-page":"3619","article-title":"Vitamin D in colorectal, breast, prostate and lung cancer: a pilot study","volume":"31","author":"Pazdiora","year":"2011","journal-title":"Anticancer Res."},{"issue":"4","key":"10.1016\/j.jsbmb.2025.106675_bib92","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1111\/j.1464-410X.2007.07019.x","article-title":"Weekly high-dose calcitriol and docetaxel in patients with metastatic hormone-refractory prostate cancer previously exposed to docetaxel","volume":"100","author":"Petrioli","year":"2007","journal-title":"BJU Int."},{"issue":"3","key":"10.1016\/j.jsbmb.2025.106675_bib93","first-page":"255","article-title":"Plasma 1,25-dihydroxy- and 25-hydroxyvitamin D and subsequent risk of prostate cancer","volume":"15","author":"Platz","year":"2004","journal-title":"Cancer Causes Control.: CCC"},{"issue":"1","key":"10.1016\/j.jsbmb.2025.106675_bib94","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/ejcn.2016.184","article-title":"Plasma 25-hydroxy vitamin D and subsequent prostate cancer risk in a nested case-control study in Japan: the JPHC study","volume":"71","author":"Sawada","year":"2017","journal-title":"Eur. J. Clin. Nutr."},{"issue":"8","key":"10.1016\/j.jsbmb.2025.106675_bib95","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1158\/1055-9965.EPI-13-1340","article-title":"Serum 25-hydroxyvitamin D concentrations and risk of prostate cancer: results from the prostate cancer prevention trial","volume":"23","author":"Schenk","year":"2014","journal-title":"Cancer Epidemiol. Biomark. Prev.: A Publ. Am. Assoc. Cancer Res. Cosponsored Am. Soc. Prev. Oncol."},{"issue":"16","key":"10.1016\/j.jsbmb.2025.106675_bib96","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1200\/JCO.2010.32.8815","article-title":"Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer","volume":"29","author":"Scher","year":"2011","journal-title":"J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol."},{"issue":"24 Pt 1","key":"10.1016\/j.jsbmb.2025.106675_bib97","doi-asserted-by":"crossref","first-page":"8680","DOI":"10.1158\/1078-0432.CCR-05-1237","article-title":"Phase I\/II Sstudy of 19-nor-1alpha-25-dihydroxyvitamin D2 (Paricalcitol) in advanced, androgen-insensitive prostate cancer","volume":"11","author":"Schwartz","year":"2005","journal-title":"Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res."},{"issue":"1","key":"10.1016\/j.jsbmb.2025.106675_bib98","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1055\/a-0774-8809","article-title":"The effect of vitamin D supplementation on prostate cancer: a systematic review and meta-analysis of clinical trials","volume":"51","author":"Shahvazi","year":"2019","journal-title":"Horm. Metab. Res. = Horm. - Und Stoffwechs. = Horm. Metab."},{"issue":"1","key":"10.1016\/j.jsbmb.2025.106675_bib99","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1159\/000343780","article-title":"High-dose calcitriol, docetaxel and zoledronic acid in patients with castration-resistant prostate cancer: a phase II study","volume":"90","author":"Shamseddine","year":"2013","journal-title":"Urol. Int."},{"issue":"12","key":"10.1016\/j.jsbmb.2025.106675_bib100","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1002\/cncr.29320","article-title":"Circulating vitamin D, vitamin D-related genetic variation, and risk of fatal prostate cancer in the national cancer institute breast and prostate cancer cohort consortium","volume":"121","author":"Shui","year":"2015","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.jsbmb.2025.106675_bib101","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1093\/jnci\/djs189","article-title":"Vitamin D-related genetic variation, plasma vitamin D, and risk of lethal prostate cancer: a prospective nested case-control study","volume":"104","author":"Shui","year":"2012","journal-title":"J. Natl. Cancer Inst."},{"issue":"1","key":"10.1016\/j.jsbmb.2025.106675_bib102","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA: A Cancer J. Clin."},{"issue":"7","key":"10.1016\/j.jsbmb.2025.106675_bib103","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1158\/1055-9965.EPI-14-0007","article-title":"Prospective population-based study of the association between serum 25-hydroxyvitamin-D levels and the incidence of specific types of cancer","volume":"23","author":"Skaaby","year":"2014","journal-title":"Cancer Epidemiol. Biomark. Prev.: A Publ. Am. Assoc. Cancer Res. Cosponsored Am. Soc. Prev. Oncol."},{"issue":"12","key":"10.1016\/j.jsbmb.2025.106675_bib104","doi-asserted-by":"crossref","first-page":"R294","DOI":"10.1530\/EC-18-0283","article-title":"Circulating vitamin D level and mortality in prostate cancer patients: a dose-response meta-analysis","volume":"7","author":"Song","year":"2018","journal-title":"Endocr. Connect."},{"issue":"9","key":"10.1016\/j.jsbmb.2025.106675_bib105","first-page":"3605","article-title":"A phase II trial of calcitriol and naproxen in recurrent prostate cancer","volume":"29","author":"Srinivas","year":"2009","journal-title":"Anticancer Res."},{"issue":"4","key":"10.1016\/j.jsbmb.2025.106675_bib106","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0125151","article-title":"Association between plasma 25-hydroxyvitamin D, ancestry and aggressive prostate cancer among African Americans and European Americans in PCaP","volume":"10","author":"Steck","year":"2015","journal-title":"PLoS ONE"},{"issue":"3","key":"10.1016\/j.jsbmb.2025.106675_bib107","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.juro.2016.03.009","article-title":"Serum vitamin D is not helpful for predicting prostate cancer aggressiveness compared with the prostate health index","volume":"196","author":"Stephan","year":"2016","journal-title":"J. Urol."},{"issue":"6","key":"10.1016\/j.jsbmb.2025.106675_bib108","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1210\/en.2011-1600","article-title":"Dietary vitamin D3 and 1,25-dihydroxyvitamin D3 (Calcitriol) exhibit equivalent anticancer activity in mouse xenograft models of breast and prostate cancer","volume":"153","author":"Swami","year":"2012","journal-title":"Endocrinology"},{"issue":"1","key":"10.1016\/j.jsbmb.2025.106675_bib109","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.eururo.2005.03.023","article-title":"Dietary intake of calcium, vitamin D, phosphorus and the risk of prostate cancer","volume":"48","author":"Tavani","year":"2005","journal-title":"Eur. Urol."},{"issue":"3","key":"10.1016\/j.jsbmb.2025.106675_bib110","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1097\/01.ju.0000169261.42298.e6","article-title":"High dose pulse calcitriol, docetaxel and estramustine for androgen independent prostate cancer: a phase I\/II study","volume":"174","author":"Tiffany","year":"2005","journal-title":"J. Urol."},{"issue":"10","key":"10.1016\/j.jsbmb.2025.106675_bib111","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1093\/aje\/kwp022","article-title":"Serum vitamin D and risk of prostate cancer in a case-control analysis nested within the European Prospective Investigation into Cancer and Nutrition (EPIC)","volume":"169","author":"Travis","year":"2009","journal-title":"Am. J. Epidemiol."},{"issue":"1","key":"10.1016\/j.jsbmb.2025.106675_bib112","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1158\/0008-5472.CAN-18-2318","article-title":"A collaborative analysis of individual participant data from 19 prospective studies assesses circulating vitamin D and prostate cancer risk","volume":"79","author":"Travis","year":"2019","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.jsbmb.2025.106675_bib113","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/sj.bjc.6604865","article-title":"Association between serum 25(OH)D and death from prostate cancer","volume":"100","author":"Tretli","year":"2009","journal-title":"Br. J. Cancer"},{"issue":"7","key":"10.1016\/j.jsbmb.2025.106675_bib114","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1111\/j.1464-410X.2009.08531.x","article-title":"Vitamin D deficiency and insufficiency among patients with prostate cancer","volume":"104","author":"Trump","year":"2009","journal-title":"BJU Int."},{"issue":"10","key":"10.1016\/j.jsbmb.2025.106675_bib115","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1002\/cncr.21890","article-title":"Phase II trial of high-dose, intermittent calcitriol (1,25 Dihydroxyvitamin D3) and dexamethasone in androgen-independent prostate cancer","volume":"106","author":"Trump","year":"2006","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.jsbmb.2025.106675_bib116","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1093\/ajcn\/81.5.1147","article-title":"Dairy, calcium, and vitamin D intakes and prostate cancer risk in the national health and nutrition examination epidemiologic follow-up study cohort","volume":"81","author":"Tseng","year":"2005","journal-title":"Am. J. Clin. Nutr."},{"issue":"1","key":"10.1016\/j.jsbmb.2025.106675_bib117","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1002\/ijc.11375","article-title":"Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: a longitudinal, nested case-control study in the nordic countries","volume":"108","author":"Tuohimaa","year":"2004","journal-title":"Int. J. Cancer"},{"issue":"2","key":"10.1016\/j.jsbmb.2025.106675_bib118","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1158\/1055-9965.EPI-06-0777","article-title":"Interaction of factors related to the metabolic syndrome and vitamin D on risk of prostate cancer","volume":"16","author":"Tuohimaa","year":"2007","journal-title":"Cancer Epidemiol. Biomark. Prev.: A Publ. Am. Assoc. Cancer Res. Cosponsored Am. Soc. Prev. Oncol."},{"issue":"6","key":"10.1016\/j.jsbmb.2025.106675_bib119","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.3390\/ijms19061618","article-title":"Role of vitamin D beyond the skeletal function: a review of the molecular and clinical studies","volume":"19","author":"Umar","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.jsbmb.2025.106675_bib120","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0959-8049(96)00373-5","article-title":"Diet and prostate cancer: a case-control study","volume":"33","author":"Vlajinac","year":"1997","journal-title":"Eur. J. Cancer (Oxf. Engl.: 1990)"},{"issue":"4","key":"10.1016\/j.jsbmb.2025.106675_bib121","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1210\/jc.2012-4019","article-title":"Randomized clinical trial of vitamin D3 doses on prostatic vitamin D metabolite levels and Ki67 labeling in prostate cancer patients","volume":"98","author":"Wagner","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"12","key":"10.1016\/j.jsbmb.2025.106675_bib122","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1002\/ijc.27969","article-title":"Circulating 25-hydroxyvitamin D, vitamin D-binding protein and risk of prostate cancer","volume":"132","author":"Weinstein","year":"2013","journal-title":"Int. J. Cancer"},{"issue":"6","key":"10.1016\/j.jsbmb.2025.106675_bib123","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0099954","article-title":"In older men, lower plasma 25-hydroxyvitamin D is associated with reduced incidence of prostate, but not colorectal or lung cancer","volume":"9","author":"Wong","year":"2014","journal-title":"PloS One"},{"issue":"1","key":"10.1016\/j.jsbmb.2025.106675_bib124","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1207\/s15327914nc5101_5","article-title":"Pilot study: potential role of vitamin D (Cholecalciferol) in patients with PSA relapse after definitive therapy","volume":"51","author":"Woo","year":"2005","journal-title":"Nutr. Cancer"},{"issue":"9","key":"10.1016\/j.jsbmb.2025.106675_bib125","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1007\/s00432-014-1706-3","article-title":"Positive association between circulating 25-hydroxyvitamin D levels and prostate cancer risk: new findings from an updated meta-analysis","volume":"140","author":"Xu","year":"2014","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.jsbmb.2025.106675_bib126","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/524206","article-title":"Vitamin D levels in subjects with prostate cancer compared to age-matched controls","volume":"2012","author":"Yaturu","year":"2012","journal-title":"Prostate Cancer"},{"issue":"6","key":"10.1016\/j.jsbmb.2025.106675_bib127","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.canep.2009.10.014","article-title":"Meta-analysis of longitudinal studies: serum vitamin D and prostate cancer risk","volume":"33","author":"Yin","year":"2009","journal-title":"Cancer Epidemiol."},{"issue":"10","key":"10.1016\/j.jsbmb.2025.106675_bib128","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1002\/ijc.31966","article-title":"Circulating 25-hydroxyvitamin D, vitamin D binding protein and risk of advanced and lethal prostate cancer","volume":"144","author":"Yuan","year":"2019","journal-title":"Int. J. Cancer"}],"container-title":["The Journal of Steroid Biochemistry and Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960076025000032?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960076025000032?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T03:57:05Z","timestamp":1777262225000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960076025000032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":128,"alternative-id":["S0960076025000032"],"URL":"https:\/\/doi.org\/10.1016\/j.jsbmb.2025.106675","relation":{},"ISSN":["0960-0760"],"issn-type":[{"value":"0960-0760","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The double disparity: Vitamin D deficiency and lethal prostate cancer in black men","name":"articletitle","label":"Article Title"},{"value":"The Journal of Steroid Biochemistry and Molecular Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsbmb.2025.106675","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"106675"}}